Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-05-27

FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)

View source ↗

Summary

FDA approved a supplemental application for JUXTAPID (lomitapide mesylate) from Amryt Pharmaceuticals DAC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JUXTAPID (lomitapide)

Snippet

SUPPL AP for JUXTAPID (LOMITAPIDE MESYLATE)